Tenpoint Therapeutics, Ltd.

Tenpoint Therapeutics, Ltd. company information, Employees & Contact Information

Tenpoint Therapeutics Limited is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts and geographic atrophy. Its lead asset, BRIMOCHOL PF, is a novel, pupil-modulating therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately 2 billion people globally. BRIMOCHOL PF has completed its first Phase 3 pivotal trial (BRIO-I) and will complete the second pivotal study, BRIO-II, in 2025. This topical ophthalmic is poised for launch in 2026. Tenpoint’s leadership team includes ophthalmic industry luminaries with track records of successful approvals and commercialization of blockbuster drugs. A privately held company, Tenpoint Therapeutics is backed by AdBio Partners, British Patient Capital, Eight Roads, EQT Life Sciences, F-Prime Capital, Hillhouse Capital Management, Qiming Venture Partners USA, Sofinnova Partners, and UCL Technology Fund.

Company Details

Employees
63
Founded
-
Address
London Innovation Centre, 20 Water Street,4th Floor Office 3
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
London
Looking for a particular Tenpoint Therapeutics, Ltd. employee's phone or email?

Tenpoint Therapeutics, Ltd. Questions

News

Tenpoint Therapeutics, Ltd. to Participate in Four Upcoming Investor Conferences - Business Wire

Tenpoint Therapeutics, Ltd. to Participate in Four Upcoming Investor Conferences Business Wire

Tenpoint Therapeutics, Ltd. to Participate in Upcoming Eye Care Conferences - Yahoo Finance

Tenpoint Therapeutics, Ltd. to Participate in Upcoming Eye Care Conferences Yahoo Finance

FDA accepts new drug application for Brimochol PF for presbyopia treatment - Healio

FDA accepts new drug application for Brimochol PF for presbyopia treatment Healio

Tenpoint Therapeutics Ltd. Appoints Melissa Epperly as Chief Financial Officer - The AI Journal

Tenpoint Therapeutics Ltd. Appoints Melissa Epperly as Chief Financial Officer The AI Journal

Tenpoint Therapeutics, Ltd. to Participate in Investor Conferences in September - Business Wire

Tenpoint Therapeutics, Ltd. to Participate in Investor Conferences in September Business Wire

Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines - Yahoo Finance

Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines Yahoo Finance

Tenpoint Therapeutics Submits NDA for BRIMOCHOL PF to Treat Presbyopia - HCPLive

Tenpoint Therapeutics Submits NDA for BRIMOCHOL PF to Treat Presbyopia HCPLive

Tenpoint Therapeutics and Visus Therapeutics complete merger, combining ophthalmic therapeutics portfolios - Ophthalmology Times

Tenpoint Therapeutics and Visus Therapeutics complete merger, combining ophthalmic therapeutics portfolios Ophthalmology Times

Tenpoint Therapeutics Taps Carol Kearney as CCO - Contract Pharma

Tenpoint Therapeutics Taps Carol Kearney as CCO Contract Pharma

Tenpoint Therapeutics Appoints Melissa Epperly as Chief Financial Officer - VisionMonday.com

Tenpoint Therapeutics Appoints Melissa Epperly as Chief Financial Officer VisionMonday.com

Tenpoint, Visus merge in effort to push presbyopia-correcting eye drop over FDA finish line - Fierce Biotech

Tenpoint, Visus merge in effort to push presbyopia-correcting eye drop over FDA finish line Fierce Biotech

Tenpoint Therapeutics Ltd. Announces FDA Acceptance of New Drug Application for BRIMOCHOL™ PF for the Treatment of Presbyopia - Business Wire

Tenpoint Therapeutics Ltd. Announces FDA Acceptance of New Drug Application for BRIMOCHOL™ PF for the Treatment of Presbyopia Business Wire

Tenpoint Therapeutics, Visus Therapeutics announce merger - Healio

Tenpoint Therapeutics, Visus Therapeutics announce merger Healio

Tenpoint Therapeutics Ltd. to Participate in Upcoming Investor Conferences in April - Business Wire

Tenpoint Therapeutics Ltd. to Participate in Upcoming Investor Conferences in April Business Wire

Tenpoint Therapeutics Ltd. Appoints Carol Kearney as Chief Commercial Officer - Business Wire

Tenpoint Therapeutics Ltd. Appoints Carol Kearney as Chief Commercial Officer Business Wire

Tenpoint Therapeutics Ltd. Submits New Drug Application to U.S. FDA for BRIMOCHOL - Business Wire

Tenpoint Therapeutics Ltd. Submits New Drug Application to U.S. FDA for BRIMOCHOL Business Wire

Tenpoint Therapeutics Announces Positive Topline Data from Phase 3 Pivotal Study, BRIO-II, of BRIMOCHOL PF for the Treatment of Presbyopia - Business Wire

Tenpoint Therapeutics Announces Positive Topline Data from Phase 3 Pivotal Study, BRIO-II, of BRIMOCHOL PF for the Treatment of Presbyopia Business Wire

Editor’s pick: Tenpoint Therapeutics - Nature

Editor’s pick: Tenpoint Therapeutics Nature

Tenpoint Therapeutics Appoints Carol Kearney as Chief Commercial Officer - VisionMonday.com

Tenpoint Therapeutics Appoints Carol Kearney as Chief Commercial Officer VisionMonday.com

FDA accepts NDA for Tenpoint Therapeutics' Brimochol PF for presbyopia - Optometry Times

FDA accepts NDA for Tenpoint Therapeutics' Brimochol PF for presbyopia Optometry Times

Tenpoint Therapeutics Ltd. to Participate in Upcoming Investor Conferences in August 2025 - BioSpace

Tenpoint Therapeutics Ltd. to Participate in Upcoming Investor Conferences in August 2025 BioSpace

Tenpoint Therapeutics Ltd. Merges With Visus Therapeutics, Inc., Names New CEO - VisionMonday.com

Tenpoint Therapeutics Ltd. Merges With Visus Therapeutics, Inc., Names New CEO VisionMonday.com

Tenpoint Therapeutics launches with $70 million in Series A financing - Healio

Tenpoint Therapeutics launches with $70 million in Series A financing Healio

Tenpoint Therapeutics and Visus Therapeutics complete merger - Healthcare Today

Tenpoint Therapeutics and Visus Therapeutics complete merger Healthcare Today

Tenpoint Therapeutics announces positive topline results from Phase 3 pivotal trial BRIO-II assessing BRIMOCHOL PF for the treatment of presbyopia - Optometry Times

Tenpoint Therapeutics announces positive topline results from Phase 3 pivotal trial BRIO-II assessing BRIMOCHOL PF for the treatment of presbyopia Optometry Times

Tenpoint Therapeutics Launches with $70 Million Series A Financing to Reverse Vision Loss Through Engineered Cell-Based Therapeutics and In Vivo Reprogramming - Business Wire

Tenpoint Therapeutics Launches with $70 Million Series A Financing to Reverse Vision Loss Through Engineered Cell-Based Therapeutics and In Vivo Reprogramming Business Wire

Tenpoint Therapeutics picks up $70M for its regenerative medicine platform to reverse vision loss - Tech Funding News

Tenpoint Therapeutics picks up $70M for its regenerative medicine platform to reverse vision loss Tech Funding News

Look sharp: Tenpoint Therapeutics closes $70M series A round to pursue vision - BioWorld MedTech

Look sharp: Tenpoint Therapeutics closes $70M series A round to pursue vision BioWorld MedTech

Tenpoint Therapeutics Raises $70M in Series A Financing - FinSMEs

Tenpoint Therapeutics Raises $70M in Series A Financing FinSMEs

UCL spinout tackling eye disease announces £57m launch | UCL News - UCL - University College London

UCL spinout tackling eye disease announces £57m launch | UCL News - UCL University College London

Tenpoint Therapeutics raises £54m for vision-restoring biotech - UKTN

Tenpoint Therapeutics raises £54m for vision-restoring biotech UKTN

Top Tenpoint Therapeutics, Ltd. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant